Seagen, a wholly owned subsidiary of Pfizer
Trial Pipeline
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
NCT04227847
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632
A Study of SGN-MesoC2 in Advanced Solid Tumors
NCT06466187
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
NCT06254495
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
NCT05983133
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
NCT05571839
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
NCT04579380
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
NCT04430738
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
NCT04404283
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
NCT03975647
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
NCT03786081
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
NCT04697628
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
NCT04569032
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 37 |
| Phase 2 | 7 |
| Phase 3 | 7 |
Therapeutic Areas
What the Pipeline for Seagen, a wholly owned subsidiary of Pfizer Shows
According to the ClinicalTrials.gov registry, Seagen, a wholly owned subsidiary of Pfizer is linked to 51 US clinical trials across every stage of research activity. Of those, 35 studies are currently recruiting — about 69% of the sponsor's indexed portfolio — and 2 are already marked complete, representing roughly 4% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Seagen, a wholly owned subsidiary of Pfizer reports 7 late-stage studies (Phase 3 and Phase 4 combined) and 44 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Seagen, a wholly owned subsidiary of Pfizer is Carcinoma, Non-Small-Cell Lung with 8 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.